Investors

Protect Your Investments and Maximize Your Returns

Whenever you want to benchmark biotechnological companies and assess their R&D pipeline and product portfolio in a broad set of indications and diseases: evidence-based decision making is key to meeting your targets.

Our unique L-Matrix Method, which consists of our exclusive L&C database, enables us to analyze an unmatched amount of literature in a quality-controlled, unbiased approach:

  • several thousands of studies (preclinical and clinical)
  • > 80 indications
  • up to 300 data points per study

Our highly customized reports deliver the most comprehensive scientific benchmarking of the assessed companies and companies` compounds. In combination with the financial evaluation, our reports result in an evidence-based evaluation process.